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ABSTRACT 26 
Expression of the transmembrane NG2 chondroitin sulphate proteoglycan (CSPG) 27 
defines a distinct population of NG2-glia.  NG2-glia serve as a regenerative pool 28 
of oligodendrocyte precursor cells (OPCs) in the adult CNS, which is important for 29 
demyelinating diseases such as Multiple Sclerosis, and are a major component of 30 
the glial scar that inhibits axon regeneration after CNS injury. In addition, NG2-31 
glia form unique neuron-glial synapses with unresolved functions. However, to 32 
date it has proven difficult to study the importance of NG2-glia in any of these 33 
functions using conventional transgenic NG2 ‘knock-out’ mice.  To overcome this, 34 
we aimed to determine whether NG2-glia can be targeted using an immunotoxin 35 
approach. We demonstrate that incubation in primary anti-NG2 antibody in 36 
combination with secondary saporin-conjugated antibody selectively kills 37 
NG2-expressing cells in vitro. In addition, we provide evidence that the 38 
same protocol induces the loss of NG2-glia without affecting astrocyte or 39 
neuronal numbers in cerebellar brain slices from postnatal mice. This study 40 
shows that targeting the NG2 CSPG with immunotoxins is an effective and 41 
selective means for killing NG2-glia, which has important implications for 42 
studying the functions of these enigmatic cells both in the normal CNS, and in 43 
demyelination and degeneration. 44 
45 
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Introduction 46 
The NG2 chondroitin sulphate proteoglycan (CSPG) is expressed in both the 47 
developing and adult central nervous system (CNS), where it marks a specific 48 
population of glial cells (Butt et al., 2002).  A primary function of NG2-glia is to 49 
act as oligodendrocyte progenitor cells (OPCs), generating oligodendrocytes 50 
during development and in the adult (Rivers et al., 2008; Etxeberria et al., 51 
2010). Most significantly, NG2-glia have been shown to form functional synapses 52 
with neurons in hippocampal, cortical, and cerebellar slices (Bergles et al., 2000; 53 
Lin et al., 2005; De Biase et al., 2010; Etxeberria et al., 2010; Ge et al., 2006; 54 
Kukley et al., 2008; Vél z-Fort et al., 2010), and with nodes of Ranvier in white 55 
matter (Butt et al., 1999; Kukley et al., 2007, Ziskin et al., 2007; Hamilton et 56 
al., 20010). In addition, NG2-glia may also perform a structural function at 57 
synapses (Stegmuller et al., 2003). A key aspect of NG2-glia is that they are 58 
highly reactive cells and respond to most forms of CNS injury by a rapid increase 59 
in proliferation and glial scar formation (Levine et al., 2001; Tan et al., 2005). 60 
Notably, NG2 is considered one of the main molecules in the glial scar that 61 
contributes to the failure of axon regeneration in the adult CNS (Sandvig et al., 62 
2004; Tan et al., 2005). Neurotransmission may serve as a regulatory 63 
mechanism for controlling the developmental progression of NG2-glia (Etxeberria 64 
et al., 2010), and a further possibility is that it regulates an injury response in 65 
NG2-glia (Hamilton et al., 2010).  Hence, regulating NG2-glia has potential 66 
significance in normal brain development and function, and in demyelination and 67 
degeneration. 68 
 69 
The functions of NG2-glia are in part directly related to the properties of 70 
the CSPG molecule (Stegmuller et al., 2003; Levine et al., 2001; Nishiyama et al, 71 
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1996b; Stallcup, 2002).  However, a line of NG2-null mice has been produced, 72 
and these did not manifest gross phenotypic differences (Grako et al., 1999). 73 
Subsequent studies have indicated subtle changes in oligodendrocytes, with a 74 
reduction in the numbers and proliferation of OPCs in developing white matter 75 
and a delay in myelination in the NG2 null mouse (Kucharova and Stallcup, 76 
2010). However, there are no apparent effects on hippocampal neurogenesis 77 
(Thallmair et al., 2006), or on axonal regeneration in the CNS and PNS (Hossain-78 
Ibrahim et al., 2007). These genetic studies did not result in the loss of NG2-glia, 79 
and so we wished to develop a system that specifically ablates these cells.  80 
Immunotoxins have been used successfully for eliminating particular neural 81 
populations on the basis of their expression of specific antigens (Wiley, 1996).  82 
Here, we demonstrate that as a membrane spanning molecule, the NG2 CSPG is 83 
an amenable target for selective immunoablation of NG2-expressing glia in vitro, 84 
and that this secondary immunoablation protocol achieves selective destruction 85 
of NG2-glia in situ in cerebellar slice organotypic cultures. 86 
87 
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Methods 88 
Animals and Tissue 89 
Experiments were performed on cell lines (C6, CTX-TNA2 and NG108-15) and on 90 
cerebellar slices from GFAP-EGFP transgenic mouse line (Nolte et al., 2001), in 91 
which the expression of enhanced green fluorescent protein (EGFP) was under 92 
the control of the human glial fibrillary acidic protein (GFAP) promoter [line 93 
TgN(GFAPEGFP) GFEC-FKi] (gift from Frank Kirchhoff, University of Goettingen). 94 
Mice aged postnatal day (P)12 were killed humanely in accordance with the 95 
Home Office Animals (Scientific) Act 1986 (UK), and brains were prepared fresh 96 
for cerebellar slice cultures or immersion fixed in 4% paraformaldehyde (PFA) in 97 
phosphate-buffered saline (PBS) for immunohistochemistry. 98 
 99 
Cell Lines and Culture Conditions 100 
C6, CTX-TNA2 and NG108-15 cell lines were obtained from European Collection 101 
of Cell Cultures as rat glioma line, transfected astrocytes and mouse 102 
neuroblastoma × rat glioma hybrid, respectively. The F98 cell line was obtained 103 
from ATCC-LGC Promochem as a rat glioma line. CTX-TNA2 and F98 cells were 104 
maintained in culture with D-MEM medium (Invitrogen) supplemented with 5% 105 
foetal bovine serum (FBS) (Invitrogen); C6 cells with F12 medium (Invitrogen) 106 
supplemented with 5% FBS and L-Glutamine (Invitrogen) to 2 mM final 107 
concentration; NG108-15 cells with D-MEM supplemented with 5% FBS, L-108 
Glutamine to 2 mM final concentration, 0.6% HAT supplement (Sigma) and with 109 
a solution of Penicillin-Streptomycin (Penicillin G sodium 10000 U/ml, 110 
Streptomycin sulphate 1000 µg/ml) diluted 1:100. Cells were cultured in an 111 
incubator at 37°C with 5%CO2 and 95% air; 75 cm
3 flasks were used for 112 
maintenance of the cell lines, and 24-well plates were used for experimental 113 
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purposes. For passaging steps, subconfluent cultures were digested with 0.25% 114 
trypsin/EDTA solution (Invitrogen) for 3-5 min, and then resuspended in culture 115 
media in a 1:10/1:20 ratio. 116 
 117 
Cerebellar slice cultures 118 
Cerebellar brain slice cultures were prepared as previously described, with some 119 
modifications (Leoni et al., 2009).  Brains from P11-13 mice were rapidly 120 
removed and placed in chilled Gey’s balanced salt solution (GBSS, Invitrogen), 121 
supplemented with 25 mM D-glucose. Cerebellar slices were cut at 300 µm using 122 
a McIlwain tissue chopper and slices were transferred into 6-well culture plates 123 
with 1 ml serum-free culture medium per well.  Medium was composed of 124 
NeurobasalTM media (Invitrogen) supplemented with B27 supplement 125 
(Invitrogen), with 1 mM glutamine (Invitrogen) and with 25 mM D-glucose 126 
(Sigma), and a solution of Penicillin-Streptomycin (Penicillin G sodium 10000 127 
U/ml, Streptomycin sulphate 1000 µg/ml, Invitrogen) diluted 1:500.  Slices were 128 
cultured at 37°C in 5% CO2 and 95% air for up to 4 days in vitro (DIV), and the 129 
culture medium was replaced every two days. Slices were regularly examined 130 
and discarded if contamination occurred.  At the end of the experiments, slices 131 
were immersion fixed in 4% PFA for 30 min at room temperature (RT) for 132 
immunohistochemistry. 133 
 134 
Immunoablation  135 
Cell cultures were exposed to different concentrations of mouse primary anti-136 
NG2 antibody (monoclonal from Upstate), alone or in combination with different 137 
concentrations of saporin-conjugated anti-mouse antibody (Mab-ZAP, Advanced 138 
Targeting Systems). Both Mab-ZAP and primary antibody were diluted in the 139 
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culture medium and the secondary conjugate was added first to avoid 140 
internalization of the primary antibody before complexing with the immunotoxin. 141 
Control groups included an untreated group (no primary antibody and no 142 
secondary immunotoxin), and single-treatment groups, where either one of the 143 
two antibodies was presented on its own at different concentrations. For each 144 
treatment, representative pictures of the cells were acquired using a digital 145 
camera adapted on a Nikon Eclipse TS100 microscope, while cell death was 146 
measured using the MTT assay as described below. 147 
 148 
Cerebellar slices were treated with two different immunotoxin combinations: (A) 149 
NG2/Mab-ZAP, consisting of mouse monoclonal anti-NG2 primary antibody (from 150 
Upstate, 1:1000), with an anti-mouse secondary antibody linked with the toxin 151 
saporin (Mab-ZAP; from ATS, 5 µg/ml); or (B) NG2/Rab-ZAP, consisting of rabbit 152 
polyclonal anti-NG2 primary antibody (from Chemicon, 1:1000) and anti-rabbit 153 
secondary immunotoxin, Rab-ZAP (from ATS, 5 µg/ml); control slices (untreated 154 
group) were cultured in culture media. Slices were treated with the anti-NG2-155 
saporin immuno-cocktail for between 2 to 4 days, and sections were analysed by 156 
immunohistochemistry (see below). 157 
 158 
Western blot and RT-PCR 159 
Cell cultures were examine for NG2 expression using western blot and RT-PCR. 160 
For western blot, proteins were extracted from the cell cultures with a lysis buffer 161 
composed of 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 162 
2 mM EGTA, 0.5 mM PMSF (phenylmethanesulphonylfluoride), 10 µg/ml 163 
leupeptin, 10 µg/ml antipain, 1 µg/ml chimostatin, 1 µg/ml pepstatinA, 5 mM 164 
Na2P2O7, 1 mM Na3VO4 and 50 mM NaF. Lysates were centrifuged at 4000 rpm 165 
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and 4ºC and supernatants were used for the Stanford colorimetric determination 166 
of the total protein content of each sample. Bovine serum albumin was used to 167 
make a standard curve and BioRad reagent was used for the protein assay. The 168 
remaining supernatants were mixed with 5X Laemmli buffer (312 mM Tris, 0.1 169 
g/ml SDS, 50% glycerol, 25% mercaptoethanol, 0.125 mg/ml bromophenol blue) 170 
to prepare the loading samples for the SDS-PAGE. 50 µg of total proteins were 171 
run on a 8% polyacrylamide gel and blotted onto nitrocellulose membranes by 172 
semi-dry electroblotting at 1.5 mA/cm2. Membranes were then blocked for 1 h at 173 
RT in a blocking solution consisting of 4% skimmed milk powder dissolved in 174 
TRIS-buffered saline (TBS) (150 mM NaCl, 10 mM Tris, pH 7.4) added of 0.05% 175 
Tween-20 (TTBS). Membranes were next incubated overnight at 4ºC with a 176 
polyclonal anti-NG2 antibody (Chemicon), diluted 1:2000 in blocking solution. 177 
The membranes were subsequently washed three times for 5 min in TTBS and 178 
then incubated for 1 h at RT in peroxidase-conjugated goat anti-rabbit IgG 179 
(1:1000, Sigma). After three further washes for 5 min in TTBS, the membranes 180 
were finally processed with the ECLTM Western blot detection system (GE 181 
Healthcare) and the Hyperfilm-ECL (GE Healthcare) for the detection of the 182 
protein bands. In some cases, clarified homogenates were digested with 183 
chondroitinase ABC in order to cleave the GAG lateral chain from the native NG2 184 
proteoglycan. 150 µl aliquots of homogenates were added of 5 mU of 185 
chondroitinase ABC (Seikagaku America Inc.) and digested for 30 min at 37°C. 186 
Digested samples were then added to 5X Laemmli buffer as described above, and 187 
stored at -20°C until use. 188 
 189 
For RT-PCR, cell cultures were washed twice in PBS and incubated for 5 min with 190 
1 ml RNABee (Biogenesis) per well. Each solution was transferred to Eppendorf 191 
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tubes and 100 µl chloroform was added to each tube, shaken by hand and left on 192 
ice for 5 min; samples were then centrifuged at 15000 rpm for 15 min at 4°C. 193 
The upper colourless phase containing the RNA was transferred in new Eppendorf 194 
tubes containing 600 µl isopropanol and centrifuged at 15000 rpm for 15 min at 195 
4°C. The supernatant was discarded and 1 ml of 75% ethanol was added to wash 196 
the pellet. Samples were then centrifuged at 8000 rpm for 8 min at 4°C, ethanol 197 
was discarded, and pellets were vacuum dried for 5 min. The resulting RNA was 198 
resuspended in 35 µl RNA resuspension buffer (10 nM Tris pH 8.0, 10 mM NaCl, 199 
1 mM EDTA) at 65°C in water bath. 5 µl aliquots of each sample were used to 200 
determine the RNA concentration and purity by determining the A260/A280 ratio 201 
with a GeneQuant spectrophotometer. The remaining RNA samples were stored 202 
at -70°C until use for the reverse transcriptase reaction. 1 µg RNA of each 203 
sample was reverse transcribed into complementary DNA (cDNA) in a final 204 
reaction volume of 20 µl containing 4 µl MgCl2 (25 mM), 2 µl 10X Buffer, 2 µl 205 
dNTPs (10 mM), 0.5 µl/ml oligo d(T)15, 0.5 µl RNase Inhibitor and 0.25 µl of M-206 
MLV Reverse Transcriptase, RNase H minus (all reagents were from Promega). 207 
The reaction was carried out at 42°C for 1 h, followed by 5 min at 95°C. 208 
Negative controls for the PCR reactions were carried out as described above, but 209 
omitting the Reverse Transcriptase and the RNase Inhibitor. cDNA samples were 210 
stored at -20°C until use. The PCR was carried out in a final reaction volume of 211 
25 µl containing 2.5 µl of cDNA, 1.5 µl MgCl2 (25 mM), 2.25 µl 10X Buffer, 1 µl of 212 
each forward and reverse primers (both 2.5 pmol/µl, synthesised by Sigma), 213 
0.125 µl dNTPs (10 mM) and 0.625 U of Taq DNA polymerase. All reagents were 214 
from Promega, except for the primers that were synthesised by Sigma as 215 
follows: 5’-CCTCAGAGCCCTATCTCCACGTAGC-3’ and 5’-216 
CATCACCAAGTAGCCAGCGTTCG-3’ (accession number NM139001). The PCR 217 
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reactions were performed in a thermal cycler (GeneAmp 9700, Applied 218 
Biosystem) with an initial denaturating step of 5 min at 94°C, and 35 cycles of 219 
annealing (55°C), extension (72°C) and denaturation (95°C), 30 sec per each 220 
step. Negative controls of each sample were also amplified in order to test that 221 
genomic DNA was absent from the cDNA samples. PCR products were run on a 222 
1% agarose gel together with a 200 bp DNA ladder (Hyper-Ladder I from Bioline 223 
Ltd) and amplified bands were visualised by fluorescence with the SYBR Safe 224 
DNA gel stain 10.000X concentrated in DMS (Invitrogen), through ultraviolet 225 
illumination with UVI/PRO transilluminator system (UVIsoft UVIband Windows 226 
Application V10.01). 227 
 228 
Immunolabelling 229 
Cell cultures and cerebellar slices were rinsed once with PBS, and fixed with 4% 230 
buffered paraformahldehyde (pH 7.4) for 30 min at RT. Cells and tissues were 231 
washed in PBS, and a blocking stage was performed by incubation for 1h at RT in 232 
blocking buffer composed of 0.1% bovine serum albumin plus 10% normal goat 233 
serum (NGS) and, in the case of brain slices, addition of 1% Triton X-100 in 234 
phosphate buffered saline (PBST). Samples were then incubated overnight at 4°C 235 
with primary antibodies diluted in blocking buffer: mouse primary anti-NG2 236 
antibody (monoclonal from Upstate, 1:500); rabbit anti-NG2 (either from Dr 237 
Stallcup, 1:500, or Chemicon, 1:200); chicken anti-GFAP (1:200; Chemicon); 238 
rabbit anti-calbindin D-28K (1:300; Chemicon). After three washes in PBST, 239 
samples were incubated for 1h at RT with the appropriate secondary antibodies 240 
conjugated with 488Alexafluor or 567Alexafluor (1:500, Molecular Probes), and in 241 
some cases Hoechst dye (Molecular Probes, 1:1000) was used for cell nuclei 242 
counterstaining. For double immunofluorescence labelling, primary antibodies of 243 
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different origin were diluted together in blocking buffer and co-dilutions of the 244 
appropriate secondary antibodies were used. After final washes in PBST, samples 245 
were mounted on poly-lysine coated glass slices with Vectashield mounting 246 
media (Vector Laboratories), and images were acquired using a LSM 5 Pascal 247 
Axioskop2 confocal microscope (Zeiss). 248 
 249 
MTT cell death assay 250 
Cell cultures we e washed once with 1X HBM solution (20 mM HEPES, 140 mM 251 
NaCl, 5 mM KCl, 5 mM NaHCO3, 1.4 mM NaH2PO4) containing 55 mM glucose and 252 
0.4 mM CaCl2. The cells were then incubated with 0.5 ml per well of 1.2 mM MTT 253 
((3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma) for 254 
1 h at 37ºC, and the MTT solution was subsequently replaced with 300 µl of 255 
DMSO to solubilise the resulting formazan product. 200 µl aliquots of each 256 
sample were finally transferred into 96-well plates, and absorbance measured at 257 
480 nm on a POLARstar Optima microplate reader (BMG LABTECH). Data were 258 
statistically analysed with the Origin Lab software. ANOVA was followed by post 259 
hoc t-test for comparing individual treatment groups. 260 
 261 
Cell counts and statistical analysis 262 
Two to four images from random fields of view (FOV; 460×460 µm at x20 263 
magnification, or 230x230 µm at x40 magnification) from n≥3 cerebellar slices 264 
were acquired on a LSM 500 confocal microscope (Zeiss), using LSM Image 265 
software (Zeiss). Acquisition parameters of magnification, laser energy source 266 
and pinhole aperture were kept constant between different treatment groups. 267 
Numbers of immunolabelled cells were counted in each FOV and means (±SEM) 268 
calculated for each treatment group. Data were analysed with GraphPad Prism 269 
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v3.02 software (GraphPad Software Inc.), and one-way or two-way ANOVA 270 
analysis was performed for all the experimental groups, followed by a post hoc t-271 
test or Tukey’s test, as appropriate. 272 
273 
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RESULTS 274 
Efficacy and specificity of NG2-cell immunoablation in vitro 275 
The immunotoxin system is based on a primary anti-NG2 antibody, and a 276 
secondary antibody that is directed against the primary antibody and to which 277 
the toxin saporin is chemically linked. The primary antibody binds specifically to 278 
the epitope on the cell surface, and provides a vehicle for the internalisation of 279 
the secondary immunotoxin, resulting in the intracellular release of the toxin 280 
saporin and cell death (Wiley, 1996; Kohls et al., 2000). To develop a specific 281 
immunoablation system for NG2-expressing cells, it was necessary to first 282 
identify cell lines which strongly expressed NG2, and others that did not express 283 
the proteoglycan. Four cell lines were selected on the basis that NG2 CSPG is 284 
expressed in glioma cells, but not neurons or astrocytes (Chekenya and 285 
Pilkington, 2002); C6 and F98 glioma cell lines, the CTX-TNA2 astrocyte cell line, 286 
and the NG108-15 neural cell line. The four cell lines were characterised for NG2 287 
expression using immunocytochemistry, Western blot, and RT-PCR (Fig. 1). The 288 
results demonstrate that the C6 and F98 glioma cells expressed high levels of 289 
NG2, whereas no NG2 protein was detected either in the astrocytic CTX-TNA2 290 
cell line or in the neuronal hybrid NG108-15 cells. Immunocytochemistry clearly 291 
demonstrate that the two glioma cell lines are immunopositive for NG2 (Fig. 1A, 292 
B), whereas CTX-TNA2 and NG108-15 cell lines are immunonegative (Fig. 1C, 293 
D). This was confirmed by western blot, where both the 300 kDa core protein 294 
and the 400 kDa native form of NG2 proteoglycan were detected in C6 and F98 295 
glioma cells (Fig. 1E); enzymatic digestion of the homogenates with 296 
chondroitinase ABC (Ch ABC) resulted in the complete conversion of the high 297 
molecular weight form of NG2 into the 300 kDa one, due to the cleavage of the 298 
GAG lateral chain from the core protein, confirming the identity of the protein 299 
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bands detected. Finally, differential expression of NG2 was demonstrated at the 300 
mRNA level by RT-PCR (Fig. 1F), amplified products displaying the predicted size 301 
of 502 bp for NG2 mRNA in both C6 and F98 glioma cell lines, whereas no mRNA 302 
was detected in the astrocytic CTX-TNA2 cells and was barely detectable in the 303 
neuronal hybrid NG108-15 cell line.  304 
 305 
On the basis of the expression analyses, the NG2-positive C6 glioma and NG2-306 
negative CTX-TNA2 astrocyte cell lines were used to optimise the secondary 307 
immunotoxin protocol. The results show that compared to controls incubation 308 
with either the primary anti-NG2 antibody alone (1:5000 or 1:500 dilutions), or 309 
the saporin-conjugated anti-mouse secondary antibody (Mab-ZAP; 1.0, 0.5 or 310 
1.0 µg/ml) had no effect on cell densities (Fig. 2A-F) or cell viability, as 311 
determined by the MTT assay (Fig. 2 G, H; p>0.05, one way ANOVA). Having 312 
shown that both primary and secondary antibodies on their own are not toxic for 313 
either C6 or CTX-TNA2 cell lines, we examined the combined effect of a range of 314 
concentrations of the mouse anti-NG2 and Mab-ZAP antibodies presented 315 
together (Fig. 3 and Table 1). Cells were examined after 72 h, and in NG2-316 
expressing C6 glioma cells immunoablation occurred in a concentration-317 
dependent manner (Fig. 3), whereas the viability of NG2-negative CTX-TNA2 318 
cells was unaffected by any of the treatments (Table 1). Thus, only NG2-positive 319 
cells were ablated in the presence of both anti-NG2 antibody and the secondary 320 
saporin-conjugated secondary antibody, demonstrating the selectivity and 321 
specificity of the NG2-immunotoxin, with greatest cell death using 1:5000 322 
dilution of primary antibody and 0.5-1.0 µg/ml of saporin-conjugated secondary 323 
antibody, consistent with a previous study targeting C6 glioma cells using the 324 
192 IgG primary antibody against the p75NTR (Kohls & Lappi, 2000). 325 
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Interestingly, the 1:5000 dilution of primary anti-NG2 antibody was more 326 
effective than the higher concentration (1:500), most likely due to excess 327 
primary anti-NG2 competitively inhibiting the binding of conjugated anti-NG2-328 
Saporin to NG2 epitopes and preventing its internalisation into the cells (Adam et 329 
al. 2006).   330 
 331 
NG2-cell immunoablation in cerebellar slice cultures 332 
The results presented above demonstrated that a combination of primary 333 
antibody against NG2 and secondary immunotoxin antibody effectively and 334 
selectively killed cultures of NG2-expressing glia, with no indirect effects of either 335 
antibody on their own. In cerebellar slices, we used both the mouse anti-NG2 336 
antibody and Mab-ZAP combination (Fig. 4), and the rabbit polyclonal anti-NG2 337 
antibody with a secondary anti-rabbit immunotoxin Rab-ZAP (NG2/Rab-ZAP) 338 
(Fig. 5). Experiments were performed on cerebellar slices from P12-15 GFAP-339 
eGFP mice in order to identify astrocytes (GFAP-EGFP+), in order to confirm the 340 
integrity of the slices and the selectivity of NG2 ablation. After 72h slices  were 341 
fixed and immunolabelled for NG2 (n≥3 per group). In controls, NG2-glia and 342 
astroglia appeared normal as previously described (Leoni et al., 2009), with 343 
NG2-glia being uniformly distributed across the layers of the cerebellum 344 
intermingled with Bergmann glia with characteristic morphology, with somata in 345 
the Purkinje cell layer (PCL), and long primary processes extending through the 346 
molecular layer (ML) to the pia (Fig. 4A-C). Notably, there was no loss or 347 
disruption of NG2-glia following treatment with NG2-Mab-ZAP (Fig. 4D-I), 348 
whereas treatment with NG2-Rab-ZAP caused a marked loss of NG2-glia (Fig. 5). 349 
Immunolabelling for NG2 was performed following washout of the immunotoxin, 350 
and the results from NG2-Mab-Zap clearly demonstrate that NG2 351 
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immunostaining per se was not disrupted by incubation in the cocktail (Fig. 4); 352 
NG2-glia exhibited their characteristic morphology of small central somata and 353 
radially extended fine branching processes (Fig. 4G-I), as described previously 354 
(Leoni et al., 2009). The loss of NG2-glia was specific to treatment with the NG2-355 
Rab-ZAP combination (Fig. 5), decreasing from 60.8 ± 8.35 cells per FOV in 356 
controls and 68.5 ± 7.64 cells per FOV in NG2-Mab-ZAP, to 22.0 ± 3.24 cells per 357 
FOV in NG2/RabZAP (Fig. 5D; p<0.001, one-way ANOVA and post hoc Tuckey’s 358 
key test). In addition, NG2-Rab-Zap had no effect on immunostaining for NeuN 359 
and synaptophysin (Fig. 6A, B) or on the general distribution or cell density of 360 
EGFP+ astrocytes (Fig. 6C, D); EGFP+ astrocytes were surrounded by 361 
degenerating NG2-glia and debris in immunotoxin-treated slices (Fig. 6E, F). The 362 
results demonstrate that NG2-Rab-Zap selectively and effectively ablates NG2-363 
glia. 364 
 365 
Following treatment with NG2-Rab-ZAP immunotoxin, the bulk of NG2 366 
immunostaining appeared as diffuse and punctate, attributable to debris of dead 367 
or dying cells (Fig. 5C, 6E).  In addition to this substantial loss of NG2-glia, 368 
compared to controls surviving NG2-glia appeared degenerative following NG2-369 
RabZAP treatment (Fig. 7A, B); this was analysed further using morphological 370 
criteria to subdivide NG2-glia into, (i) normal process bearing cells (Fig. 7C), (ii) 371 
amoeboid reactive cells (Fig. 7D), or (iii) severely ‘injured’ cells characterised by 372 
fragmented immunostaining (Fig. 7E). The vast majority of NG2-glia in control 373 
slices (n=44 cells) were classified as normal (39%) or amoeboid reactive (61%) 374 
cells, and no visibly injured cells were identified (Fig. 7F). The situation was 375 
reversed following treatment with NG2/Rab-ZAP (Fig. 7G), with 81% of surviving 376 
NG2-glia appearing severely injured and 16% amoeboid reactive, with very few 377 
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cells appearing normal (3%).  Note that compared to controls, only 30% of cells 378 
survived the immunotoxin treatment (Fig. 5D), and the vast majority of these 379 
were severely disrupted (Fig. 7G). Furthermore, we have previously reported 380 
that NG2-glia begin to express the astroglial EGFP reporter in cerebellar cultures 381 
(Leoni et al., 2009), and most of the NG2-glial cells surviving immunotoxin 382 
treatment appeared to express the EGFP reporter (Fig. 8), suggesting these cells 383 
may be less susceptible to immunoablation. 384 
  385 
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DISCUSSION 386 
In the CNS, the NG2 CSPG is strongly expressed in NG2-glia, pericytes and 387 
certain gliomas (Butt et al., 2002; Nishiyama et al., 2007; Chekenya & 388 
Pilkington, 2002). One approach to study cellular function is to use genetic 389 
ablation, but NG2 knock-out mice did not result in the destruction of NG2-glia 390 
and there were only subtle effects on the CNS (Kucharova and Stallcup, 2010). 391 
Hence, we strove to develop an immunotoxin approach to target the destruction 392 
of NG2-glia in situ, using antibodies directed against the NG2 CSPG in 393 
combination with a secondary immunotoxin conjugated to saporin. The primary 394 
antibody targets the extracellular domain of the NG2 CSPG and serves as the 395 
vehicle by which the secondary immunotoxin antibody is internalised into the 396 
NG2-expressing cells. Our results show that this approach is highly effective for 397 
the selective ablation of NG2-expressing cells in vitro and ex vivo in cerebellar 398 
slices. 399 
 400 
Immunoablation of NG2-glia was effective after 72h, consistent with in vivo 401 
studies examining immunoablation of neurons, which require long-term infusion 402 
of immunotoxins via cannulae (Kwok et al., 1999; Pizzo et al., 1999; Wiley et al., 403 
1991).  This reflects the time required for the anti-NG2 primary antibody to bind 404 
to the cell surface epitope, form a tertiary complex with the secondary 405 
immunotoxin, which must then be internalised for saporin to be released and 406 
initiate apoptosis (Wiley, 1996; Kohls et al., 2000). We found the mouse 407 
monoclonal anti-NG2-saporin was very effective at selectively ablating NG2-408 
expressing C6 glioma cells in vitro, but was totally ineffective in brain slices. The 409 
reason for this is unknown, but presumably the NG2-Mab-Zap complex was not 410 
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effectively internalised in brain slices, demonstrating the importance of testing 411 
multiple antibodies to identify the most efficacious combinations. 412 
 413 
The anti-NG2-saporin immunotoxin effectively destroyed NG2-glia without 414 
adversely affecting astrocyte or neuronal densities. Furthermore, the vast 415 
majority of surviving NG2-glia appeared severely disrupted, possibly in the 416 
process of dying. In addition, NG2-glia in cerebellar slice cultures begin to 417 
express EGFP astroglial reporter after 48h (Leoni et al., 2009), and we found that 418 
these cells preferentially survived immunoablation at 72h. These GFAP-419 
EGFP+/NG2+ cells appear to display an astrocyte-oligodendrocyte (AO) lineage 420 
phenotype, which has been reported by Kirchhoff and colleagues (personal 421 
communication) and is reminiscent of the O-2A cells described by Raff and 422 
colleagues (Raff et al., 1983). NG2-glia have been reported to generate 423 
astrocytes during development, but do not normally do so in the adult (Zhu et 424 
al., 2008). It seems likely that AO cells generated in the cerebellar slice are in 425 
the process of losing NG2 and gaining GFAP as they differentiate into astrocytes 426 
(Leoni et al., 2009), and it is possible that down-regulation of the NG2 CSPG 427 
protects them from the anti-NG2-saporin immunotoxin.  428 
 429 
Our results show it is possible to target NG2-glia in situ, and this approach holds 430 
promise for studying the effects of NG2-glial cell ablation in vivo. Saporin-431 
conjugated immunotoxins have been used to effectively target specific 432 
populations of neurons in vivo, such as those directed against the p75NTR in 433 
cholinergic neurons (Wiley et al., 1991, 1995), the dopamine transporter (DAT) 434 
in dopaminergic neurons (Wiley et al., 2003), and a range of other neuronal 435 
targets, including the norepinephrine synthesizing enzyme dopamine β 436 
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hydroxylase (DβH), NK1 receptor for the Substance P, the IL-2 receptor, 437 
vasopressin and others (Wiley, 1996).  Our findings indicate it would be possible 438 
to use the same approach to examine the functions of NG2-glia in vivo.  439 
 440 
In summary, our study shows that immunoablation is a feasible option for 441 
specifically targeting NG2-glia in situ. In light of the potential importance of NG2-442 
glia, it is perhaps surprising, or at the least disappointing, that NG2 knock-out 443 
mice have failed to reveal any critical effects in the CNS (Hossain-Ibrahim et al., 444 
2007, Thallmair et al., 2006; Kucharova and Stallcup, 2010). However, a 445 
comparison can be made with astrocytes, where knock-out of GFAP, which 446 
characterises astrocytes, did not result in a loss of astrocytes or disrupt their 447 
functions (Pekny et al., 1995). The immunoablation approach provides a useful 448 
experimental tool for investigating the function of NG2-glia in both physiological 449 
and pathological conditions, such as demyelination and degeneration, and could 450 
also prove useful in experiments investigating the influence of oligodendroglial 451 
cells on cognitive functions, for example learning and memory.  452 
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Figure legends 565 
Figure 1. NG2 expression in cell lines. C6, F98, NG108-15 and CTX-TNA2 cell 566 
lines were tested for NG2 expression using immunocytochemistry (A-D), western 567 
blot (E) and RT-PCR (F). (A-D) Cells were immunolabelled for NG2 (green) with a 568 
mouse monoclonal antibody from Upstate (1:500) and cell nuclei stained with 569 
Hoechst 33342 dye (blue). C6 (A) and F98 (B) rat glioma cells express the NG2 570 
antigen on their cell surface, whereas the CTX-TNA2 (C) and NG108-15 (D) cell 571 
lines do not express NG2. Scale bar, 50 µm. (E) Western blotting revealed 572 
protein expression of the NG2 CSPG in the C6 and F98 cell lines, whereas the 573 
NG108-15 and CTX-TNA2 cell lines were NG2-negative. The arrows and the 574 
arrowheads indicate the 300 kDa core protein and the 400 kDa native form of 575 
NG2, respectively, in samples treated (+) with Chondroitinase ABC (Ch ABC), or 576 
prior to enzymatic digestion (-). Treatment with ChABC determined the complete 577 
conversion of the native form into the 300 kDa one, in both C6 and F98 cell lines. 578 
(F) RT-PCR confirmed C6 and F98 cell lines express NG2 mRNA, while NG108-15 579 
and CTX-TNA2 cell lines were negative. A mouse brain extract was used in both 580 
Western blot and RT-PCR as a positive control, and molecular weight markers are 581 
shown on the left. 582 
 583 
Figure 2. Lack of toxicity of either primary or secondary antibodies 584 
in vitro. (A-F) C6 glioma cells were exposed for 72 h to control culture 585 
media (A), or to either anti-NG2 primary antibody (α1) alone (B-C) or 586 
saporin-conjugate anti-mouse secondary immunotoxin (ZAP) alone (D-F), 587 
at different concentrations. Neither of the two antibodies had any toxicity 588 
on the C6 cells, compared to the untreated control group. Scale bar, 100 589 
µm. (G, H) C6 cells (G) and CTX-TNA2 (H) cells were exposed for 72 h to 590 
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either anti-NG2 primary antibody (α1) or saporin-conjugated anti-mouse 591 
secondary immunotoxin (ZAP), at different concentrations, and cell 592 
viability measured using the MTT assay. Neither of the two antibodies had 593 
any significant toxicity on C6 or CTX-TNA2 cells, compared to the 594 
untreated control group. Data are expressed as mean±SEM. 595 
 596 
Figure 3. Immunoablation of NG2-positive C6 cells. C6 cells were 597 
exposed for 72 h to a combination of Mab-ZAP and primary anti-NG2 598 
antibody (α1) at different concentrations. (A-H) Cell density was clearly 599 
reduced following treatment with NG2-Mab-ZAP; Scale bar, 100 µm. (I) 600 
Cell viability measured by the MTT assay was significantly decreased 601 
following treatment with the combined NG2-Mab-ZAP. For each treatment, 602 
n=4. One way ANOVA analysis (p<0.05) was performed over the three 603 
treatment groups. *p<0.05, **p<0.01, ***p<0.001, post hoc t-test vs 604 
intra-group controls (0 ZAP). 605 
 606 
Figure 4. Mouse anti-NG2 immunotoxin (NG2/Mab-ZAP) does not affect 607 
NG2-glia in cerebellar slice cultures. Cerebellar slices from P13 GFAP-EGFP 608 
mice were cultured for 4DIV, and then fixed and immunolabelled for NG2.  609 
Confocal images illustrate the separate channels for NG2 immunolabelling (A, D, 610 
G, red), GFP expression (B, F, H, green), and the combined channels (C, F, I).  611 
(A-C) Control slices cultured in normal serum-free medium (CTR). (D-I) Slices 612 
exposed for 4 days to a combination of mouse anti-NG2 primary antibody and 613 
Mab-ZAP secondary antibody (NG2/Mab-ZAP). NG2 immunolabelling (A, D, G) 614 
and EGFP astroglial reporter protein (B, E, H) show no substantial toxicity of the 615 
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treatment to either population of cells. Arrowheads in (A) indicate NG2-616 
immunopositive vascular pericytes, whereas arrows in (F) indicate NG2-glial cells 617 
expressing EGFP. Asterisks in (G) and (I) illustrate in detail the morphology of 618 
NG2-glial cells that were unaffected by the NG2/Mab-ZAP treatment. These NG2-619 
glial cells were found closely associated with a presumptive Purkinje cell body, 620 
indicated by the star in (G-I). GCL, granular cell layer; PCL, Purkinje cell layer; 621 
ML, molecular layer. 622 
 623 
Figure 5. Effective immunoablation of NG2-glia in the cerebellum by the 624 
NG2/Rab-ZAP immunotoxin. Representative confocal micrographs of 625 
cerebellum slices immunolabelled for NG2 after immersion culture for 2DIV, in 626 
either control conditions (A), a combination of mouse anti-NG2 antibody and 627 
Mab-ZAP (B), or rabbit anti-NG2 antibody and Rab-ZAP (C). Only NG2-Rab-Zab 628 
caused ablation of NG2-glia; Scale bars, 20 µm. (D) Cell counts of NG2 629 
immunopositive cells in cerebellum slices expressed as mean number of cells per 630 
fields of view of 30 µm stack confocal images acquired at fixed acquisition 631 
parameters of magnification, laser source energy, pinhole aperture and stack 632 
interval (1 µm). *p<0.05, ***p<0.001, one-way ANOVA and post hoc Tukey’s 633 
test. 634 
 635 
Figure 6. Selective immunoablation of NG2-glia. Confocal micrographs of 636 
control and immunotoxin-treated (NG2/Rab-ZAP) cerebellum slices. (A, B) 637 
Cerebellar slices obtained from P11 wt mice were cultured for 3DIV in culture 638 
media (A) or Rab-ZAP (B) and then immunolabelled for NeuN (red) and 639 
synaptophysin (green), revealing no gross differences between the groups.  (C-640 
F) Treatment of P13 cerebellum slices for 3 DIV from GFAP-GFP mice 641 
Page 28 of 38Journal of Anatomy
For Peer Review Only
 29
immunolabelled for NG2 (red), with normal medium (C) or NG2/Rab-ZAP 642 
immunotoxin (D-F).  There were no gross differences in the number and 643 
distribution of astrocytes in the two treatment groups (C, D), and higher 644 
magnification shows viable astrocytes surrounded by NG2-immunopositive debris 645 
(E), and NG2-glia with fragmented labelling (F). 646 
 647 
Figure 7. Effect of immunoablation on the morphology of NG2-glia. 648 
Cerebellar slices obtained from P12 mice were immersion cultured for 3DIV and 649 
immunolabelled for NG2. (A) NG2-glial cells in control slices had a characteristic 650 
stellate processes-bearing morphology. (B) NG2-glial cell in slice treated with the 651 
NG2/Rab-ZAP immunotoxin were severely disrupted and NG2 immunolabelling 652 
appeared in ‘clumps’. (C-D) NG2-glia in slices treated with the NG2/Rab-ZAP 653 
immunotoxin were ranked in three morphological classes, corresponding to 654 
process-bearing (C), amoeboid reactive (D) and condensed and fragmented cells 655 
(E). (F, G) Pie-chart analysis of the proportions of NG2-glia with the different 656 
morphologies expressed as number of cells per FOV of 30 µm confocal stack. 657 
 658 
Figure 8. GFAP-EGFP-expressing NG2-glia survive immunoablation. NG2-659 
glial cells that expressed the astroglial reporter protein GFAP-EGFP displayed 660 
resistance to the immunotoxin treatment. (A) Confocal 30 µm z-stack (Ai) and 661 
single 1 µm z-zections (Aii, Aiii) illustrating viable NG2-glia expressing the GFAP-662 
EGFP reporter, in the proximity of severely disrupted NG2+/EGFP- cells.  (B) 663 
Confocal z-stack of NG2-glial cell expressing the GFAP-EGFP reporter, showing 664 
the combined channels (Bi) and single channel analysis of NG2 immunolabelling 665 
(Bii) and EGFP expression (Biii).  Three-dimensional reconstructions of the 666 
NG2+/EGFP+ cell in orthogonal projections (Biv) and following isoforming (Bv) 667 
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illustrate the cytoplasmic EGFP reporter and cell membrane NG2 668 
immunolabelling. 669 
 670 
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